This is an international site for Exjade® (Deferasirox) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional I am a patient inside of the US I am a patient outside the U.S.

Home > Sickle Cell Disease > Overview
Print

In patients with sickle cell disease

Sickle Cell Disease

Transfusions and Iron Chelation Are Integral
for Overall Supportive
Care Management

Sickle cell disease (SCD) is a blood-related disorder that is genetically based, and is most common in people of sub-Saharan African ethnic origin. In regions of sub-Saharan Africa, up to 2% of all children may have sickle cell disease and there are 200,000 new cases per year in Africa1; however, it is no longer a localized disorder. Sickle cell disease is prevalent in India, Saudi Arabia, France, the Mediterranean, Latin America, and the United States.

The stiff, sickle-shaped blood cells characterizing SCD prevent oxygen circulation. Pain crises, as well leg ulcers, gallstones, high blood pressure in the lungs, enlarged spleen, stroke and other complications can occur. Newborns should be screened for the disorder, so that treatment can be initiated early.1


Reference

  1. World Health Organization. Sickle-Cell Anaemia. Fifty-Ninth World Health Assembly, Provisional Agenda Item 11.4.
    http://www.who.int/gb/ebwha/pdf_files/WHA59/A59_9-en.pdf. Published April 2006. Accessed November 8, 2010    .

EXCESS IRON CAN ACCUMULATE AND LEAD TO TISSUE TOXICITY

Transfusional iron can
lead to debilitating
consequences if left
untreated. Learn
more about the risks
of iron toxicity
in SCD patients.

EXJADE PROVIDES ONCE-DAILY ORAL CHELATION

EXJADE can help remove excess iron in patients with transfusion-dependent sickle cell disease.

Learn more

TRANSFUSION-DEPENDENT
β-THALASSEMIA		 MYELODYSPLASTIC SYNDROMES SICKLE CELL DISEASE APLASTIC AND OTHER ANEMIAS TOOLS AND RESOURCES ALL ABOUT EXJADE

EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with β-thalassemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusion in patients aged 2 years and older with β-thalassemia major or other anemias when deferoxamine is contraindicated or inadequate.
Disclaimer: This is an international website for Exjade, and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
© Novartis AG | Use of this website is subject to our Terms of Use | About Novartis Oncology | Privacy | Site Map | Contact Us | EU SmPC | Safety Information | PubMed